Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$18.57 USD
-0.63 (-3.28%)
Updated Sep 25, 2025 04:00 PM ET
Pre-Market: $18.57 0.00 (0.00%) 8:18 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELVN 18.57 -0.63(-3.28%)
Will ELVN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for ELVN
NR7 appears for ELVN after 0.05% move
ELVN Fell Below 20 Day Moving Average on September 23
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuticals Inc
Is ELVN ready to move higher? Crossed Above 20 Day Moving Average shows up after rocketing 5.06%
Is ELVN lining up for a decline? 20 Day Moving Average Resistance shows up after sliding 4.84%